Leflunomide | C12H9F3N2O2 - PubChem
Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review - ScienceDirect
Nuclear Factor κB Signaling in Atherogenesis | Arteriosclerosis, Thrombosis, and Vascular Biology
NF-κB signaling in rheumatoid arthritis with focus on fibroblast-like synoviocytes | Autoimmunity Highlights | Full Text
Nuclear factor-κB: its role in health and disease | SpringerLink
Chemical structures of leflunomide and its metabolite A77 1726. | Download Scientific Diagram
Leflunomide | C12H9F3N2O2 - PubChem
New Drugs for Rheumatoid Arthritis | NEJM
Higher Levels of Leflunomide Are Associated with Hemolysis and Are not Superior to Lower Levels for BK Virus Clearance in Renal Transplant Patients | American Society of Nephrology
Cancers | Free Full-Text | Targeting NF-κB Signaling for Multiple Myeloma | HTML
Cancers | Free Full-Text | Targeting NF-κB Signaling for Multiple Myeloma | HTML
Effects of Leflunomide on Hyaluronan Synthases (HAS): NF-κB-Independent Suppression of IL-1-Induced HAS1 Transcription by Leflunomide | The Journal of Immunology
NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis - ScienceDirect
Cancers | Free Full-Text | Targeting NF-κB Signaling for Multiple Myeloma | HTML
The role of Chinese herbal medicine in the management of adverse drug reactions of leflunomide in treating rheumatoid arthritis - ScienceDirect
Individualization of leflunomide dosing in rheumatoid arthritis patients | Personalized Medicine
Leflunomide Suppresses TNF-Induced Cellular Responses: Effects on NF-κB, Activator Protein-1, c-Jun N-Terminal Protein Kinase, and Apoptosis | The Journal of Immunology
Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial - The Lancet Rheumatology
Effect of leflunomide (2.5, 5 or10 mg/kg) on hepatic immunostaining for... | Download Scientific Diagram
Frontiers | Pathomechanisms of bone loss in rheumatoid arthritis
Effects of Leflunomide on Hyaluronan Synthases (HAS): NF-κB-Independent Suppression of IL-1-Induced HAS1 Transcription by Leflunomide | The Journal of Immunology
Inhibiting NF-κB activation by small molecules as a therapeutic strategy. - Abstract - Europe PMC
Individualization of leflunomide dosing in rheumatoid arthritis patients | Personalized Medicine
NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis - ScienceDirect
Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial - The Lancet Rheumatology
Individualization of leflunomide dosing in rheumatoid arthritis patients | Personalized Medicine
The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function | Arthritis Research & Therapy | Full Text
